Rheumatoid Arthritis
Rheumatoid Arthritis Market

Rheumatoid Arthritis is a chronic, inflammatory autoimmune disease and leads to a progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints.


Rheumatoid Arthritis Epidemiological Segmentation 

The Epidemiological Segmentation of Rheumatoid Arthritis in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases of Rheumatoid Arthritis
  • Total Diagnosed Prevalent Cases of Rheumatoid Arthritis
  • Gender-specific Prevalent Cases of Rheumatoid Arthritis
  • Age-specific Prevalent Cases of Rheumatoid Arthritis
  • Severity-specific Prevalent Cases of Rheumatoid Arthritis
  • Patients on targeted therapies of Rheumatoid Arthritis
  • Line-Wise Treated Cases of Rheumatoid Arthritis


Rheumatoid Arthritis Epidemiology 

  • The total prevalent cases of Rheumatoid Arthritis in 7MM were 4,356,793 in 2017
  • The prevalent cases of Rheumatoid Arthritis in the United States were 1,333,290 in 2017


Rheumatoid Arthritis Market

The market size of Rheumatoid Arthritis in 7MM in 2017 was USD 21.2 Billion


Rheumatoid Arthritis Market Drivers

  • Increase in the prevalence population of Rheumatoid Arthritis
  • Increase in geriatric population
  • Rich Emerging Pipeline


Rheumatoid Arthritis Market Barriers

  • The high cost of Biologics
  • Low adherence to the drugs
  • Heterogeneity of Rheumatoid Arthritis


Rheumatoid Arthritis Emerging Drugs

The emerging drugs of the Rheumatoid Arthritis market are 

  • GSK3196165 (otilimab/MOR103)
  • Filgotinib (GS-6034; GLPG0634; Jyseleca)
  • Olokizumab
  • TS-152 (Ozoralizumab)
  • ATI-450 (CDD-450)
  • VIB4920
  • Branebrutinib
  • ABBV-3373 and ABBV-154
  • Dekavil (F8IL10)
  • PF-06651600 (Ritlecitinib)
  • JTE 051
  • Evobrutinib (M2951)
  • PF-06650833
  • Fenebrutinib (GDC-0853, RG7845)
  • MPC-300-IV (Allogeneic Mesenchymal Precursor Cells)
  • Bimekizumab
  • Namilumab (IZN-101; AMG203)
  • ABX464
  • HB-AdMSCs
  • SKI-O-703

And many others.  


Rheumatoid Arthritis Key Players

The key players in the Rheumatoid Arthritis market are

  • GlaxoSmithKline
  • Gilead
  • Galapagos NV
  • R-Pharm
  • Taisho Pharmaceuticals
  • Aclaris Therapeutics
  • Viela Bio
  • Bristol Myers Squibb
  • AbbVie
  • Pfizer
  • Philogen
  • Akros Pharma
  • Japan Tobacco
  • Merck KGaA
  • Genentech (subsidiary of Roche)
  • Mesoblast
  • UCB Pharma
  • PRA HEALTH SCIENCES
  • Izana Bioscience
  • Takeda
  • Abivax S.A.
  • Hope Biosciences
  • Genosco (Oscotec)

And many others.